drugset
drugset / Trial / NCT04406415

Oral Nafamostat in Healthy Volunteers (NAF-101)

NCT04406415 ↗

Phase 1 Completed 17 enrolled Ensysce Biosciences National Institute on Drug Abuse (NIDA) · collab
RandomizedSequentialSingle-blindTreatment

Summary

This is a randomized, double-blind, placebo-controlled Multiple Ascending Dose (MAD) study to evaluate the safety, tolerability and pharmacokinetics of oral nafamostat solution administered t.i.d.. for up to 5 days in healthy volunteer adult subjects

Timeline

Start
2020-09-21
Primary completion
2020-11-11
Completion
2021-05-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Nafamostat Small molecule 10 mg Oral
Subject Nafamostat Small molecule 50 mg Oral
Subject Nafamostat Small molecule 100 mg Oral
Subject Nafamostat Small molecule 200 mg Oral

Indications

No indication recorded.